Trial of Adcetris in CD30+ Malignant Mesothelioma

Study Drug Administration:

There are 21 days (about 3 weeks) in each study cycle.

If you are found to be eligible to take part in this study, you will receive brentuximab
vedotin by vein over about 30 minutes on Day 1 of every cycle.

Length of Study:

You may continue taking the study drug for as long as the doctor thinks it is in your best
interest. You will no longer be able to take the study drug if the disease gets worse, if
intolerable side effects occur, or if you are unable to follow study directions.

Your participation on this study will be over after you have completed follow-up (described
below).

Study Visits:

On Day 1 of every cycle:

- You will have a physical exam

- Blood (about 4 teaspoons) will be drawn for routine tests

Every 6 weeks while you are on study, you will have a PET-CT scan to check the status of the
disease.

Follow-Up:

The study doctor or study team will follow you up with you about 30 days after your last dose
of brentuximab vedotin by either reviewing your medical record or calling you to learn if you
have had any side effects.

You will continue to have these follow-ups at 3 months, 6 months, and then every 6 months
after that while you are on study.

Inclusion Criteria:

1. Voluntary written informed consent before performance of any study-related procedure
not part of normal medical care, with the understanding that consent may be withdrawn
by the subject at any time without prejudice to future medical care.

2. Female subject is either: a. post-menopausal for at least one year before the
screening visit; or b. surgically sterilized; or c. willing to use an acceptable
method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm
with spermicide, condom with spermicide, or abstinence) for the duration of the study
and at least 6 months after the last dose of brentuximab vedotin.

3. Male subject, even if surgically sterilized (ie, status postvasectomy), agrees to use
an acceptable barrier method for contraception (condom with a spermicidal agent), or
completely abstain from heterosexual intercourse during the entire study treatment
period through 6 months after the last dose of brentuximab vedotin.

4. Absolute neutrophil count (ANC) > 1500/mm³, platelets > 100,000/mm³, Hgb > 8.5 g/dL.

5. Total bilirubin ULN. AST and/or ALT may be up to 5X ULN if with known liver mets

6. Adequate renal function as defined by: Calculated creatinine clearance must be >/= 30
mL/minute

7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

8. Pathologic diagnosis of malignant mesothelioma (any primary site is acceptable, any
histology is acceptable)

9. Have unresectable malignant mesothelioma (any histology)

10. Positive CD30+ immunohistochemical expression

11. Any line of prior therapy - patients may be chemo-naïve or chemo-refractory (any line)

12. Patients must have measurable disease by modified RECIST or RECIST. Examinations for
assessment of measurable disease must have been completed within 28 days prior to
registration.

13. Patient must be >/= 18 years of age

Exclusion Criteria:

1. Radiation therapy to more than 25% of the bone marrow. Whole pelvic radiation is
considered to be over 25%.

2. Prior allogeneic bone marrow or organ transplantation

3. Female subject who is pregnant or breast-feeding. Confirmation that the subject is not
pregnant must be established by a negative serum Beta-human chorionic gonadotropin
(B-hCG) pregnancy test result obtained during screening. Pregnancy testing is not
required for post-menopausal or surgically sterilized women.

4. Patient has received other investigational drugs with 14 days before enrollment

5. Serious medical or psychiatric illness likely to interfere with participation in this
clinical study.

6. No prior history of malignancy within 2 years, unless cured of a skin cancer or a
stage I-III solid tumor. No prior hematologic malignancy within 3 years.

7. Known hypersensitivity to brentuximab vedotin components

8. Persons who are incarcerated at time of enrollment (e.g., prisoners) or likely to
become incarcerated during the study.